Citadel Advisors’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Citadel Advisors’s Portfolio PVCT Stock Details PVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-178,100	Closed	-$66K	–	8194
2016 Q2	$66K	Sell	178,100 -83,619	-32%	-$31.8K	﹤0.01%	6341
2016 Q1	$99K	Buy	+261,719	New	+$108K	﹤0.01%	6034
2015 Q3	–	Sell	-76,699	Closed	-$41K	–	9511
2015 Q2	$41K	Buy	76,699 +47,338	+161%	+$38.6K	﹤0.01%	7805
2015 Q1	$24K	Buy	29,361 +6,636	+29%	+$5.47K	﹤0.01%	7810
2014 Q4	$18K	Buy	+22,725	New	+$20.8K	﹤0.01%	7907
2014 Q3	–	Sell	-21,748	Closed	-$19K	–	8663
2014 Q2	$19K	Buy	+21,748	New	+$26.1K	﹤0.01%	7328

Other funds holding PVCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Citadel Advisors's PVCT Position: Q3 2016 in Review

Citadel Advisors sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q3 2016, closing a stake of 178,100 shares — an estimated $66K sold.

Citadel Advisors first reported a position in PVCT in Q2 2014 and held it in 6 quarters. The position peaked at $99K in Q1 2016. 41 funds tracked by Wall St. Rank hold PVCT as of Q3 2016.

Citadel Advisors reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q3 2016 after selling out during the quarter.
Citadel Advisors sold 178,100 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q3 2016, an estimated $66K.
Citadel Advisors first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q2 2014 and held it in 6 quarters.
Citadel Advisors's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $99K in Q1 2016.
41 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q3 2016.

Based on Citadel Advisors's 13F filing for Q3 2016, filed 10 Nov 2016.